Clinical and immunogenetic correlates of abacavir hypersensitivity

被引：119

作者：

Phillips, EJ ^{[1
]}

Wong, GA

Kaul, R

Shahabi, K

Nolan, DA

Knowles, SR

Martin, AM

Mallal, SA

Shear, NH

机构：

[1] Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada

[2] Univ Liverpool, Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool L69 3BX, Merseyside, England

[3] Univ Toronto, Hlth Network, Toronto, ON, Canada

[4] Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada

[5] Royal Perth Hosp, Ctr Clin Immunol & Biomed Stat, Perth, WA, Australia

来源：

AIDS | 2005年 / 19卷 / 09期

关键词：

D O I：

10.1097/01.aids.0000171414.99409.fb

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A patch test (PT) may be useful in defining true abacavir hypersensitivity syndrome (AHS). Seven previously PT-positive patients remote from the original AHS were shown to have robust 24 h responses, supporting PT durability. HLA-B*5701 was present in all seven PT-positive versus one of 11 controls tolerating abacavir (P < 0.001). Five of seven PT (71%) versus one of 11 controls (9%) (P = 0.005) showed significant abacavir-specific CD8 proliferation, suggesting a direct role for HLA-B*5701-restricted CD8 cells in the pathophysiology of AHS.

引用

页码：979 / 981

页数：3

共 9 条

[1]

Easterbrook P J, 2003, HIV Med, V4, P321, DOI 10.1046/j.1468-1293.2003.00166.x

[2] Genetic variations in HLA-B region and hypersensitivity reactions to abacavir [J].

Hetherington, S ;

Hughes, AR ;

Mosteller, M ;

Shortino, D ;

Baker, KL ;

Spreen, W ;

Lai, E ;

Davies, K ;

Handley, A ;

Dow, DJ ;

Fling, ME ;

Stocum, M ;

Bowman, C ;

Thurmond, LM ;

Roses, AD .

LANCET, 2002, 359 (9312) :1121-1122

[3] Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir [J].

Hetherington, S ;

McGuirk, S ;

Powell, G ;

Cutrell, A ;

Naderer, O ;

Spreen, B ;

Lafon, S ;

Pearce, G ;

Steel, H .

CLINICAL THERAPEUTICS, 2001, 23 (10) :1603-1614

[4] Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations [J].

Hughes, AR ;

Mosteller, M ;

Bansal, AT ;

Davies, K ;

Haneline, SA ;

Lai, EH ;

Nangle, K ;

Scott, T ;

Spreen, WR ;

Warren, LL ;

Roses, AD .

PHARMACOGENOMICS, 2004, 5 (02) :203-211

[5] Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J].

Mallal, S ;

Nolan, D ;

Witt, C ;

Masel, G ;

Martin, AM ;

Moore, C ;

Sayer, D ;

Castley, A ;

Mamotte, C ;

Maxwell, D ;

James, I ;

Christiansen, FT .

LANCET, 2002, 359 (9308) :727-732

[6] Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant [J].

Martin, AM ;

Nolan, D ;

Gaudieri, S ;

Almeida, CA ;

Nolan, R ;

James, I ;

Carvalho, F ;

Phillips, E ;

Christiansen, FT ;

Purcell, AW ;

McCluskey, J ;

Mallal, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (12) :4180-4185

[7]

Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845

[8] Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir [J].

Phillips, EJ ;

Sullivan, JR ;

Knowles, SR ;

Shear, NH .

AIDS, 2002, 16 (16) :2223-2225

[9] Common HLA-B8-DR3 haplotype in Northern India is different from that found in Europe [J].

Witt, CS ;

Price, R ;

Kaur, G ;

Cheong, K ;

Kanga, U ;

Christiansen, F ;

Sayer, D ;

Mehra, NK .

TISSUE ANTIGENS, 2002, 60 (06) :474-480

← 1 →